… BCR-ABL. Currently, there are five tyrosine kinase inhibitors (TKIs) approved for the treatment
… Second generation (2G) TKIs demonstrated faster and higher rates of response compared …

… It induces apoptosis and inhibits proliferation in BCR/ABL–… In 2010, FDA announced that
second generation of TKIs (dasatinib … Our studies mostly investigated imatinib resistant patients …

… kinase inhibitor (2GTKI) after failure of a first-generation TKI … the 3 main subsets of imatinib
resistant/intolerant patients: … activity in vitro against most BCR-ABL mutations, but not T315I [73…

… In addition, the seven-year follow-up of the CA180-034 study, which involved both
imatinib-resistant and -intolerant patients switched to dasatinib, has demonstrated that 100 mg once …

… inhibitor, is the first choice in chronic myeloid leukemia … BCR/ABL mutations and response
to imatinib treatment in terms … rate of pyrosequencing in imatinib-resistant patients was 15.6%, …

… -ABL1 T315I -driven chronic myeloid leukemia–like disease and … % of imatinib-resistant
CML patients overall, second-generation … model of CML and syngeneic BCR/ABL-induced ALL …

… of BCR-ABL tyrosine kinase. Imatinib (1st TKIs) was developed with the intention of treating
chronic myeloid … (a 3rd-generation inhibitor) in 2021 for chronic myeloid leukemia. Out of 50 …

… the chronic myeloid leukemia signaling pathway via the depletion of BCR-ABL that was
mediated by the inhibition of … activity against imatinib-resistant CML cells carrying T315I-mutated …

… hypothesized that pharmacological inhibition of HDAC3 could … to have the efficacy for inhibition
of deubiquitinase (DUB) … to stabilize BCR-ABL and to promote BCR-ABL kinase signaling …

… The development of ABL1 tyrosine kinase inhibitors (TKI) for the treatment of chronic
myeloid leukemia (CML) is an … Charting the molecular network of the drug target Bcr-Abl. …